Literature DB >> 28138652

Advances in the diagnosis and treatment of gastric neuroendocrine neoplasms.

Huangying Tan1.   

Abstract

Gastric neuroendocrine neoplasms (g-NENs) are a group of heterogeneous tumors arising from the endocrine cells of stomach. Most g-NENs progresses slowly and have a long disease course; however, some other g-NENs grow rapidly, similar to the progression of gastric adenocarcinoma. g-NENs have complex and diverse clinical manifestations and their prognosis and treatment strategies depend highly on clinical subtype, pathological grade, tumour stage, and other factors. Due to their low prevalence, most clinicians have limited knowledge about g-NENs. Missed diagnosis and excessive/inadequate treatment is common in clinical settings. Thus, the diagnosis and treatment of g-NENs needs to be further standardized.

Entities:  

Keywords:  Gastric neuroendocrine neoplasms; g-NENs

Year:  2016        PMID: 28138652      PMCID: PMC5244774          DOI: 10.21037/tgh.2016.11.03

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN: 2415-1289


  26 in total

1.  Well-differentiated gastric tumors/carcinomas.

Authors:  Philippe Ruszniewski; Gianfranco Delle Fave; Guillaume Cadiot; Paul Komminoth; Daniel Chung; Beata Kos-Kudla; Reza Kianmanesh; David Hochhauser; Rudolf Arnold; Hakan Ahlman; Stanislas Pauwels; Dik J Kwekkeboom; Guido Rindi
Journal:  Neuroendocrinology       Date:  2007-02-20       Impact factor: 4.914

2.  [Autoimmune metaplastic atrophic gastritis, G cell hyperplasia and neuroendocrine tumor of stomach].

Authors:  Guangyong Chen; Shoufang Huang
Journal:  Zhonghua Bing Li Xue Za Zhi       Date:  2014-01

3.  Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.

Authors:  Constantin S Jianu; Reidar Fossmark; Unni Syversen; Øyvind Hauso; Vidar Fykse; Helge L Waldum
Journal:  Scand J Gastroenterol       Date:  2010-12-07       Impact factor: 2.423

Review 4.  Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion.

Authors:  C J Gilligan; G P Lawton; L H Tang; A B West; I M Modlin
Journal:  Am J Gastroenterol       Date:  1995-03       Impact factor: 10.864

Review 5.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

6.  Consensus guidelines for the management and treatment of neuroendocrine tumors.

Authors:  Pamela L Kunz; Diane Reidy-Lagunes; Lowell B Anthony; Erin M Bertino; Kari Brendtro; Jennifer A Chan; Herbert Chen; Robert T Jensen; Michelle Kang Kim; David S Klimstra; Matthew H Kulke; Eric H Liu; David C Metz; Alexandria T Phan; Rebecca S Sippel; Jonathan R Strosberg; James C Yao
Journal:  Pancreas       Date:  2013-05       Impact factor: 3.327

7.  Lanreotide in metastatic enteropancreatic neuroendocrine tumors.

Authors:  Martyn E Caplin; Marianne Pavel; Jarosław B Ćwikła; Alexandria T Phan; Markus Raderer; Eva Sedláčková; Guillaume Cadiot; Edward M Wolin; Jaume Capdevila; Lucy Wall; Guido Rindi; Alison Langley; Séverine Martinez; Joëlle Blumberg; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2014-07-17       Impact factor: 91.245

8.  Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs.

Authors:  D Campana; F Nori; R Pezzilli; L Piscitelli; D Santini; E Brocchi; R Corinaldesi; P Tomassetti
Journal:  Endocr Relat Cancer       Date:  2008-03       Impact factor: 5.678

9.  FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3.

Authors:  O Hentic; P Hammel; A Couvelard; V Rebours; M Zappa; M Palazzo; F Maire; G Goujon; A Gillet; P Lévy; P Ruszniewski
Journal:  Endocr Relat Cancer       Date:  2012-11-06       Impact factor: 5.678

10.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

View more
  1 in total

1.  Clinical outcomes of gastroduodenal neuroendocrine tumors according to their WHO grade: A single-institutional retrospective analysis.

Authors:  Dae Gon Ryu; Su Jin Kim; Cheol Woong Choi; Dae Hwan Kang; Hyung Wook Kim; Su Bum Park; Hyeong Seok Nam; Si Hak Lee; Sun Hwi Hwang
Journal:  Medicine (Baltimore)       Date:  2022-09-16       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.